| 29.5415 0.809 (2.82%) | 10-15 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 35.9 | 1-year : | 37.63 |
| Resists | First : | 30.73 | Second : | 32.22 |
| Pivot price | 29.94  |
|||
| Supports | First : | 28.34 | Second : | 23.57 |
| MAs | MA(5) : | 29.22 |
MA(20) : | 30.36 |
| MA(100) : | 31.87 |
MA(250) : | 32.2 |
|
| MACD | MACD : | -0.8 |
Signal : | -0.8 |
| %K %D | K(14,3) : | 17.3 |
D(3) : | 12.5 |
| RSI | RSI(14): 39.2 |
|||
| 52-week | High : | 37.15 | Low : | 27.02 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ OZEM ] has closed above bottom band by 35.7%. Bollinger Bands are 7.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 29.71 - 29.89 | 29.89 - 30.07 |
| Low: | 28.54 - 28.75 | 28.75 - 28.95 |
| Close: | 29.22 - 29.53 | 29.53 - 29.83 |
Roundhill considers weight loss medications, particularly GLP-1 agonists, to be among the most groundbreaking innovations currently reshaping the global pharmaceutical landscape. This conviction underpins the Roundhill GLP-1 & Weight Loss ETF (OZEM), which is distinguished as the world's inaugural ETF exclusively focused on the GLP-1 and broader weight management sector. Notably, OZEM employs an active management approach.
Tue, 22 Sep 2026
5 Best GLP-1 Stocks for 2026 and How to Invest - The Motley Fool
Wed, 10 Jun 2026
Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market - The Globe and Mail
Fri, 17 Apr 2026
3 Ways to Invest in the Growing GLP-1 Weight Loss Market - MarketBeat
Fri, 30 Jan 2026
OZEM Vs. THNR: Which Is The Better ETF In The GLP-1 And Weight Loss Space? - Seeking Alpha
Mon, 12 Jan 2026
New Year, New Strategy: Navigating Weight Loss ETFs - ETF Trends
Wed, 11 Jun 2025
Weight-Loss Drug ETFs Generate Skinnier Returns Than Expected - The Daily Upside
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|